Eugenol, an essential oil component in plants, has been demonstrated to possess activity against both Gram-positive and Gram-negative bacteria. This study examined the influence that subinhibitory concentrations of eugenol may have on the expression of the major exotoxins produced by Staphylococcus aureus. The results from a tumor necrosis factor (TNF) release assay and a hemolysin assay indicated that S. aureus cultured with graded subinhibitory concentrations of eugenol (16 to 128 g/ml) dose dependently decreased the TNF-inducing and hemolytic activities of culture supernatants. Western blot analysis showed that eugenol significantly reduced the production of staphylococcal enterotoxin A (SEA), SEB, and toxic shock syndrome toxin 1 (the key exotoxins to induce TNF release), as well as the expression of ␣-hemolysin (the major hemolysin to cause hemolysis). In addition, this suppression was also evaluated at the transcriptional level via real-time reverse transcription (RT)-PCR analysis. The transcriptional analysis indicated that 128 g/ml of eugenol remarkably repressed the transcription of the S. aureus sea, seb, tst, and hla genes. According to these results, eugenol has the potential to be rationally applied on food products as a novel food antimicrobial agent both to inhibit the growth of bacteria and to suppress the production of exotoxins by S. aureus.
Staphylococcus aureus is a major nosocomial pathogen. This species is capable of causing a wide range of diseases and is often associated with high morbidity and mortality rates. The disease spectrum includes food-borne illness, cutaneous infections, endocarditis, pneumonia, septic arthritis, and osteomyelitis (24, 36) . The diversity is, in part, dependent on the secretion of a broad spectrum of soluble extracellular proteins. These proteins include enterotoxins, hemolysins, toxic shock syndrome toxin 1 (TSST-1), and others (20) . S. aureus infections are difficult to control due to a combination of toxinmediated virulence, invasiveness, and antibiotic resistance. Therefore, there is a continuing need to discover new and improved antimicrobial agents to treat S. aureus illnesses, with potential benefits for both the food and pharmaceutical industries (35) .
Enterotoxins, TSST-1, and ␣-hemolysin are among the major exotoxins secreted by S. aureus. Staphylococcal enterotoxins (SEs) are a group of major serological heat-stable enterotoxins (SEA to SEE and SEG to SEJ) (3) . These toxins cause staphylococcal gastroenteritis, food poisoning, toxic shock-like syndromes, and several allergic and autoimmune diseases (3, 22, 35) . TSST-1 is the key causative toxin of toxic shock syndrome (TSS), which is an acute-onset and potentially lifethreatening staphylococcal syndrome (23) . Furthermore, SEs and TSST-1 are also known to be pyrogenic toxin superantigens (PTSAgs) that stimulate the proliferation of T lymphocytes and the release of T-cell-derived cytokines (12) . ␣-Hemolysin is a 33-kDa pore-forming soluble protein that has hemolytic, cytolytic, and dermonecrotic activities. Several types of human cells are affected by ␣-hemolysin, including erythrocytes, lymphocytes, monocytes, macrophages, and epithelial cells. Similar to the majority of proteins secreted by S. aureus, SEs, TSST-1, and ␣-hemolysin are produced primarily during the postexponential phase of growth and their expression levels are regulated by a network of interacting regulators. These include the SarA protein family (30) and many two-component regulatory systems, such as the agr (31) and sae (15) systems. The agr two-component system is one of the best-studied regulatory loci. Expression of agr is activated when bacterial cultures enter the postexponential growth phase in a cell densitydependent manner (34) . Induction of agr expression results in RNAIII production, which leads to a reduced production of several surface proteins and facilitates the production of numerous extracellular proteins (29) .
Eugenol (4-allyl-2-methoxyphenol) is a major component of clove oil and used primarily as a flavoring agent in food and cosmetic products. Studies have shown that eugenol possesses various biological abilities, including antimicrobial, antioxidant, anti-inflammatory, anticarminative, and antispasmodic activities (14, 16, 25, 27) . It has long been known that certain antibiotics can influence the expression of staphylococcal exotoxins. Therefore, the goal of this study was to assess the impact of subinhibitory eugenol concentrations on the production of TSST-1, the major enterotoxins, i.e., SEA and SEB, and alpha-hemolysin by methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA).
MATERIALS AND METHODS
Bacterial strains and reagents. MSSA strain ATCC 29213 was obtained from the American Type Culture Collection (ATCC). In total, 25 S. aureus isolates (8 MSSA and 17 MRSA) were acquired from clinical samples at the First Hospital of Jilin University in Changchun, China. Among these, clinical MRSA strains 2985 and 3701, which have the ability to produce TSST-1, ␣-hemolysin, SEA, and SEB, were chosen for further experimentation. Mueller-Hinton broth (MHB) was purchased from BD Biosciences, Inc. (Sparks, MD), and eugenol was purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions were prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich).
MIC determination. MICs of eugenol for S. aureus were assessed in triplicate using the microdilution method, as recommended by the Clinical and Laboratory Standards Institute (11) . MICs were defined as the lowest drug concentrations that inhibited growth.
Growth curves. Bacteria were cultured at 37°C to an optical density at 600 nm (OD 600 ) of 0.3 in MHB, and 100-ml volumes of the respective cultures were aliquoted into six 250-ml Erlenmeyer flasks. Five of the cultures were supplemented with eugenol (dissolved in DMSO) at concentrations of 1/16ϫ MIC (16 g/ml), 1/8ϫ MIC (32 g/ml), 1/4ϫ MIC (64 g/ml), 1/2ϫ MIC (128 g/ml), and 1ϫ MIC (256 g/ml). The final DMSO concentration for all cultures was 1% (vol/vol). The control culture contained only 1% DMSO. Following the addition of eugenol (or DMSO), bacteria were grown at 37°C with constant shaking under aerobic conditions. Cell growth was monitored by measuring the OD 600 at 30-min intervals. Bacterial cultures with various concentrations of eugenol were grown to an OD 600 of 2.5, and serial 10-fold dilutions of the samples were spread onto drug-free Mueller-Hinton agar plates. The number of colonies was determined after an incubation period of 24 h at 37°C.
TNF release assay. The tumor necrosis factor (TNF) release assay was performed according to a slightly modified method described previously by Bernardo et al. (5) . Overnight cultures of MSSA ATCC 29213, MRSA 2985, and MRSA 3701 that were grown in RPMI 1640 (Invitrogen, CA) were diluted 30-fold into 500 ml of prewarmed RPMI 1640. Following incubation at 37°C for 30 min with aeration, cultures were divided into 100-ml aliquots. Increasing concentrations of eugenol (1/16ϫ, 1/8ϫ, 1/4ϫ, and 1/2ϫ MIC) were added to the bacterial suspensions. Following the addition of eugenol, cultures were further incubated for 4 h. The final DMSO concentration for all cultures was 1% (vol/vol). The eugenol-free culture was treated with 1% DMSO alone. S. aureus supernatants without eugenol treatment served as control samples. All supernatants collected were filtered via a 0.2-m filter and immediately analyzed as described below.
Animal experiments were conducted in accordance with the experimental practices and standards approved by the Jilin University Animal Welfare and Research Ethics Committee. Specific-pathogen-free BALB/c mice (male, 6 to 8 weeks old, weighing 18 to 22 g) were supplied by the Jilin University Experimental Animal Center (Changchun, China). Mice were euthanized by cervical dislocation. Single-spleen-cell suspensions were prepared in RPMI 1640 and washed and resuspended in complete RPMI 1640 (RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 IU/ml penicillin, 100 IU/ml streptomycin, 15 mM HEPES, and 50 M 2-mercaptoethanol). A total of 10 6 (150 l) cells were seeded into 96-well tissue culture plates. These wells were then supplemented with 50 l of S. aureus culture supernatants. After incubation for 16 h, the supernatants were collected and centrifuged (1,000 ϫ g for 5 min). The TNF levels from the supernatants were analyzed using the mouse TNF-␣ ELISA Max set standard (Biolegend, Inc., San Diego, CA), in accordance with the manufacturer's instructions.
Hemolysin assay. Bacteria were cultured in MHB at 37°C with graded subinhibitory concentrations of eugenol until the postexponential growth phase was reached (OD 600 ϭ 2.5, equivalent to 1.0 ϫ 10 9 CFU/ml). Hemolytic activities of bacterial culture supernatants were assessed according to the method of Rowe and Welch (33) . Bacterial cultures were centrifuged (5,500 ϫ g, 4°C, 1 min), the supernatant was collected, and the residual cells were removed using a 0.2-m filter. Prior to the addition of 25 l of defibrinated rabbit blood, a 0.1-ml volume of culture supernatant was brought up to a volume of 1 ml through the addition of phosphate-buffered saline (PBS) buffer. After incubation for 15 min at 37°C, the unlysed blood cells were pelleted by centrifugation (5,500 ϫ g, room temperature, 1 min). The hemolytic activity of the supernatant was detected by measuring the optical density at 543 nm. The control culture supernatant served as the 100% hemolysis control, and the percent hemolysis was calculated by comparison with the control culture.
Western blot analysis. S. aureus strains were cultured in a method similar to that described above, which allowed the supernatant samples to be collected in the same manner as that used for the hemolysin assay. A 25-l volume of culture supernatant was loaded onto a 12% sodium dodecyl sulfate-polyacrylamide gel after boiling in Laemmli sample buffer (21) . The Western blot protocol was performed as described by Qiu et al. (32) and in the product guide for Amersham ECL Western blotting detection reagents (GE Healthcare, Buckinghamshire, United Kingdom). Antibodies to SEA, SEB, and ␣-hemolysin were purchased from Sigma-Aldrich and diluted to 1:10,000, 1:5,000 and 1:8,000, respectively; then, a horseradish peroxidase-conjugated anti-rabbit antiserum (Sigma-Aldrich) diluted to 1:4,000 was used as the secondary antibody. The antibody to TSST-1 (Santa Cruz Biotechnology, Santa Cruz, CA) was diluted to 1:200 according to the manufacturer's recommendations, and then a horseradish peroxidase-conjugated anti-mouse antiserum (Sigma-Aldrich) diluted to 1:5,000 was used as the secondary antibody.
Real-time RT-PCR. Strain ATCC 29213 was grown to the postexponential growth phase (t ϭ 240 min) in MHB at 37°C either without eugenol or with 128 g/ml of eugenol. RNA was prepared as described by Qiu et al. (32) . Briefly, cells were harvested by centrifugation (5,000 ϫ g for 5 min at 4°C) and resuspended into TES buffer (10 mM Tris-Cl, 1 mM EDTA, 0.5% SDS) containing 100 g/ml of lysostaphin (Sigma-Aldrich). Following incubation at 37°C for 10 min, a Qiagen RNeasy Maxi column was used to isolate total bacterial RNA, which was in accordance with the manufacturer's instructions. The contaminating DNA was removed using the optional on-column RNase-free DNase I step (Qiagen, Hilden, Germany). RNA concentrations were detected from the OD 260 , and the RNA was loaded onto an RNase-free 2% agarose gel to test for generalized degradation. The primer pairs used in real-time reverse transcription (RT)-PCR are listed in Table 1 . RNA was reverse transcribed into cDNA using the Takara RNA PCR kit (AMV) version 3.0 (Takara, Kyoto, Japan), according to the manufacturer's protocol. The resulting cDNA was stored at Ϫ20°C until it was required. The PCRs were carried out in a 25-l volume and contained SYBR Premix Ex Taq (Takara), as recommended by the manufacturer. The reactions were performed using the model 7000 sequence detection system (Applied Biosystems, Courtaboeuf, France). Cycling conditions were as follows: 95°C for 30 s; 40 cycles at 95°C for 5 s, 55°C for 30 s, and 72°C for 40 s; and one dissociation step of 95°C for 15 s, 60°C for 30 s, and 95°C for 15 s. All samples were analyzed in triplicate, and the 16S rRNA housekeeping gene served as an internal control to normalize the expressional levels between samples. The relative expression levels were analyzed by the ⌬⌬CT method that is described in the Applied Biosystems user bulletin no. 2 (1).
Statistical analysis. SPSS 12.0 statistical software was applied to analyze the experimental data. The data are presented as the mean values Ϯ standard deviations (SD). An independent Student's t test was used to determine statistical differences, and a P value of Ͻ0.05 was considered to be statistically significant.
RESULTS
Influence of eugenol on S. aureus growth. The eugenol MIC for each of the 26 S. aureus strains examined was assessed. The values obtained ranged from 128 to 512 g/ml. The MIC values of eugenol against S. aureus ATCC 29213, MRSA 2985, and MRSA 3701 were 256 g/ml. These data indicate that the eugenol structure could be used as a basic structure for the development of novel and more potent drugs to treat S. aureus infections.
To examine the effect of subinhibitory eugenol concentrations on the production of bacterial virulence factors, we ini- tially investigated the influence of graded sublethal concentrations of eugenol on the growth of S. aureus. To do this, a growth curve assay was performed. As shown in Fig. 1 , eugenol concentrations from 1/16ϫ MIC to 1/2ϫ MIC had no significant effects on the growth of S. aureus. However, when cultured with 1ϫ MIC of eugenol, the growth rate was significantly decreased: after 30, 210, and 420 min of eugenol treatment, the OD 600 values of S. aureus ATCC 29213 cultured in MHB were 58.1%, 49.2%, and 55.6%, respectively, those of cultures receiving no treatment or lower concentrations of eugenol. Although the growth kinetics can vary greatly between strains, the growth of MRSA 2985 and MRSA 3701 were affected by these concentrations of eugenol in a similar manner. In other words, MRSA 2985 and MRSA 3701 supplemented with 1/16ϫ, 1/8ϫ, 1/4ϫ, and 1/2ϫ MIC of eugenol had no significant influence on growth (data not shown). In addition, we further investigated the relationship between the OD values and number of CFU. The results obtained indicate that the levels of bacteria in the control culture and the eugenol-treated (1/16ϫ, 1/8ϫ, 1/4ϫ, and 1/2ϫ MIC) cultures were approximately 1.0 ϫ 10 9 CFU/ml when grown to an OD 600 value of 2.5.
Eugenol represses TNF-inducing and hemolytic activities of S. aureus culture supernatants. It is well known that secreted proteins in S. aureus have the ability to stimulate T lymphocytes to release proinflammatory cytokines (e.g., TNF-␣), while hemolysins produced by S. aureus cause hemolysis of rabbit erythrocytes. Therefore, TNF release and hemolysin assays were carried out to investigate the influence of eugenol on the TNF-inducing and hemolytic activities of S. aureus culture supernatants.
As shown in Fig. 2 , the culture supernatants of S. aureus grown in the presence of graded subinhibitory concentrations of eugenol elicited much lower levels of spleen cell TNF-␣ production. A 1ϫ MIC of eugenol dissolved in RPMI 1640 alone did not directly induce or reduce TNF release at (data not shown). Of importance, eugenol diminished the TNF-inducing activity of S. aureus supernatants in a dose-dependent manner.
When S. aureus strains ATCC 29213, MRSA 2985, and MRSA 3701 were treated with 1/16ϫ MIC of eugenol, the hemolysis of culture supernatants from those strains were 41.8%, 51.5%, and 60.4% of their control cultures, respectively. Remarkably, no hemolytic activities were detected when these strains were cultured with eugenol at concentrations of 1/4ϫ MIC or 1/2ϫ MIC ( Table 2 ). This dose-dependent hemolysis reduction was observed in all of the investigated strains. Furthermore, treatment with eugenol at 1ϫ MIC or 2ϫ MIC did not directly cause or inhibit hemolysis of rabbit erythrocytes. Additionally, there was little influence on the hemolytic activity of culture supernatants when preincubated with a 2ϫ MIC of eugenol (data not shown).
Eugenol represses TSST-1, SEA, SEB, and ␣-hemolysin levels in S. aureus culture supernatants. Among S. aureus secreted proteins, TSST-1 and enterotoxins are the most important exoproteins that could act as superantigens, stimulating release of T-cell-derived cytokines by spleen cells. Additionally, ␣-hemolysin is the major hemolysin that is responsible for the hemolytic activity of S. aureus culture supernatants. To determine whether the reduced TNF-inducing and hemolytic activities of S. aureus culture supernatants in the presence of various subinhibitory concentrations of eugenol were due to the diminished production of TSST-1, SEA, SEB (i.e., the major enterotoxins of S. aureus), and ␣-hemolysin, the culture supernatants were subjected to Western blot analysis. S. aureus ATCC 29213, MRSA 2985, and MRSA 3701 were grown with graded subinhibitory concentrations of eugenol to the postexponential growth phase (an OD 600 value of 2.5). As shown in Fig. 3 , treatment with eugenol resulted in a dose-dependent decrease in the production of TSST-1, SEA, SEB, and ␣-hemolysin.
Eugenol represses the transcription of S. aureus tst, sea, seb, hla, and agrA. As eugenol remarkably decreased the production of S. aureus TSST-1, SEA, SEB, and ␣-hemolysin, we therefore hypothesized that eugenol could affect the transcription of tst, sea, seb, and hla. Therefore, real-time RT-PCR was performed to detect the relative expression levels of tst, sea, seb, and hla. Additionally, the production of TSST-1, SEB, and ␣-hemolysin are positively regulated by the agr two-component system (30); therefore, the transcription level of agrA was also evaluated. As expected, the transcription levels of these genes were significantly decreased in strain ATCC 29213 upon treatment with eugenol (Table 3) . When cultured with a 1/2ϫ MIC of eugenol, the transcriptional levels of tst, sea, seb, hla, and agrA were decreased by 10.4-, 6.3-, 12.8, 15.6, and 5.5-fold, respectively.
DISCUSSION
Similar to that of other Gram-positive bacteria, the pathogenicity of S. aureus is, to a great extent, dependent upon the secretion of numerous extracellular virulence factors. Consequently, the clinical performance of antibiotics for the treatment of S. aureus is determined not only by their respective bactericidal or bacteriostatic activities but also by their effects on the release of virulence factors (5) . In addition, an alternative strategy for the treatment of S. aureus infections, one that is now gaining great interest, is targeting bacterial virulence. This alternative strategy provides promising opportunities to abate pathogenicity and its consequences without placing an immediate life-or-death pressure on the target bacterium (8) .
Previous studies have shown that the use of many antibiotics at suboptimal concentrations, which have little or no influence on cell growth, could substantially affect the expression of bacterial exotoxins. This mode of suppression has been reported to include the production of proteins such as ␣-and ␥-hemolysin, enterotoxins A and B, coagulase, and TSST-1 (5, 13, 17, 20) . These antibiotics are recommended for the treatment of severe staphylococcal illnesses associated with the secretion of these toxins. In the present study, we have shown via transcriptional, expressional, and phenotypic analyses that subinhibitory concentrations of eugenol dose-dependently decrease the production of ␣-hemolysin, TSST-1, SEA, and SEB in both MSSA and MRSA. These data suggest that the structure of eugenol could be used as a fundamental structure for the development of antimicrobial agents aimed at the bacterial virulence factors.
In the food industry, essential oils (EOs) extracted from plants have been used primarily for flavoring and fragrance (4). It has long been known that EOs have antimicrobial activities, and recent studies have demonstrated that these properties are attributable to the presence of numerous substituted aromatic molecules. These molecules include eugenol, cinnamaldehyde, and carvacrol (18, 19, 26) . Currently, there is a trend in food processing to avoid the application of chemical preservatives such as NaCl and nitrates. Thus, the use of bioactive compounds derived from EOs as alternative antimicrobial agents is garnering great interest (14, 37) . Eugenol, the major phenolic compound and antimicrobial component of clove oil, has been registered by the European Commission for use as a flavoring ingredient in foodstuffs and is considered to pose no risk to consumer health (7) . Eugenol has been reported to inhibit the growth of Escherichia coli, Listeria monocytogenes, and S. aureus (4, 6) . In addition to antibacterial activities, eugenol also possesses antifungal and antiviral activities (2, 9) . Because of its antimicrobial properties, eugenol has the potential to be used as a food antimicrobial agent.
Staphylococcal gastroenteritis and food poisoning do not result from the ingestion of S. aureus itself but rather from enterotoxins that are preformed within the food (22, 35 importantly, SEs are heat-stable enterotoxins that can resist high temperature without losing their biological activity (3). Therefore, apart from the inhibition of the growth of vegetative bacterial cells, food microbiologists are also interested in the inhibition of toxin expression (7) . The findings in our study that eugenol could substantially inhibit the production of enterotoxins when used at sublethal concentrations without an effect on bacterial growth may increase the likelihood for eugenol to be used as a novel natural food preservative. Indeed, many genes encoding virulence factors are coordinately regulated in response to a variety of intracellular and extracellular signals. It has been shown that subinhibitory concentrations of antibiotics may interfere with the translation of one or more regulatory gene products in S. aureus, which in turn affects transcription of exoprotein-encoding genes. For instance, the effect of subinhibitory concentrations of licochalcone A on ␣-hemolysin production may partially depend on the inhibition of the agr two-component system (32) . Furthermore, subinhibitory concentrations of clindamycin differentially repress the transcription of S. aureus exoprotein genes and act partially through sar (17) . Therefore, it is tempting to speculate that eugenol-induced inhibition of global regulators might lead to a decrease in the secretion of virulence-related exoproteins. To address this hypothesis, real-time RT-PCR was carried out to evaluate the effect of eugenol on the S. aureus agr locus. Our results indicate that agrA transcription was significantly reduced when S. aureus was cultured with a 1/2ϫ MIC of eugenol to the postexponential growth phase. Nevertheless, the mechanisms by which S. aureus regulates virulence gene expression are extremely complicated. This regulation involves an interactive, hierarchical regulatory cascade among the agr, sar, and other regulatory gene products (10) . Since the expression levels of TSST-1, SEB, and ␣-hemolysin are positively controlled by agr (1a, 28), we presume that the influence of subinhibitory concentrations of eugenol on the production of these toxins may depend, in part, on eugenolinduced inhibition of the agr two-component system. The agr locus has no effect on SEA expression (1a, 28) . Therefore, it is clear that the effect of eugenol on SEA secretion cannot be mediated through interactions with agr. However, the action of regulatory genes other than agr on SEA production in S. aureus remains unclear. Consequently, the regulatory mechanisms involved in the eugenol-induced reduction of SEA remain to be determined.
